Products/Services Used | Details | Operation |
---|---|---|
Peptide Synthesis> | via treatment with a synthetic peptide [23] (synthesized by Genscript) or via treatment with the smallmolecule inhibitors Cercosporin or Calphostin C [24–26]. The peptide used in this study was previously published [23] and was shown to inhibit binding of LEF1 to β-catenin. | Get A Quote |
Acute myeloid leukemia (AML) is the most common acute leukemia in adults and is propagated by leukemic stem cells (LSCs), often characterized by deregulated Wnt signaling. We previously showed that the central transcriptional mediator of Wnt signaling LEF1 is able to cause AML in mice and acts as an independent prognostic factor in normal karyotype AML. Here, we show that treatment naïve normal karyotype AML as well as samples AML LSCs predominantly express the long β-catenin-binding isoform of LEF1 in sharp contrast to normal human hematopoietic stem cells, which lack expression of the long isoform, but express the short N-terminally truncated isoform with loss of the β-catenin-binding site. Gene expression... More